Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses

Incyte Corporation (NASDAQ:INCY) on Sunday revealed the first clinical data from two studies evaluating the safety, tolerability, and efficacy of INCA033989 for mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms (MPNs).

MPNs are a group of rare blood cancers where the bone marrow produces too many blood cells (red blood cells, white blood cells, or platelets).

These data, featured at the European Hematology Association 2025 (EHA2025), focus on the dose escalation portion of the studies in patients with high risk essential thrombocythemia (ET) who are resistant/intolerant to prior cytoreductive therapy.

Also Read: Incyte’s New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls

The studies evaluated the safety and efficacy of INCA033989 in patients with ET as measured by hematologic response and reduction in mutCALR variant allele frequency (VAF).

As of April 4, 2025, results showed rapid and durable normalization of platelet counts across all dose levels, with a trend toward improved responses in higher doses (>400 mg) in patients with ET treated ...